Return-path: <>
Envelope-to: lbaez@edenetsa.com
Delivery-date: Tue, 04 Nov 2014 04:30:25 -0400
Received: from [75.187.36.204] (port=54063 helo=cpe-75-187-36-204.columbus.res.rr.com)
	by host8.dnns.net with smtp (Exim 4.82)
	id 1XlZVQ-0001xw-Kg
	for lbaez@edenetsa.com; Tue, 04 Nov 2014 04:30:25 -0400
Received: from unknown (HELO localhost) (verkoop@maine207.org@114.81.184.108)
	by 75.187.36.204 with ESMTPA; Tue, 4 Nov 2014 03:33:42 -0500
From: verkoop@maine207.org
To: lbaez@edenetsa.com
Subject: Trading Up on Strong News
Date: Tue, 4 Nov 2014 03:21:16 -0500

"Oncolytics Biotech" Biotechnology Company focuses on the development 
of oncolytic viruses for their further use in the treatment of various 
forms of tumors. The leading company's product - "REOLYSIN" - is 
currently in the final stage of clinical trials against cancer of head 
and neck. The product's action is based on the reovirus (Respiratory 
Enteric Orphan virus) ability to identify and "infect" the cells with 
the mutated RAS gene. After mutation the gene transforms an ordinary 
cell into a cancer one. "REOLYSIN", developed by the Canadian firm 
"Oncolytics Biotech Inc", not only finds the cancer cells with the 
mutated gene, but is also cytocidal. Provided that 2/3 of tumors have 
cells with the mutated RAS gene, it is hoped that complex and even 
propagating tumors might be treated without radiation and 
chemotherapy.

In accordance with recent data, the use of the reovirus medicine in 
conjunction with chemotherapeutic treatment increases the ratio of 
fortunate result for the treatment of the head and neck tumors up to 
74%.

"Oncolytics Biotech Inc (ONCY)" Company's shares are available on 
NASDAQ since 2001, Market Cap 72.36M, rated by Zacks "Strong Buy". As 
of the end of trading on 03/11/2014, the share price was $0.88, which 
is a good entry point for investing in new emerging technologies.

Let us recall that "Oncolytics Biotech Inc" Company was founded in 
Calgary in 1998 in response to developments made on the oncolytic 
potential of reovirus at the University of Calgary during the 1990s. 
In 1999-2000 the enterprise changed its ownership from private to 
public. 

The firm was issued its first Canadian patent in August 2000, and at 
present owns more than 200 patents across the globe, including 38 U.S. 
and 11 Canadian patents.